Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Illumina's TruSight One Panel; Life Tech's Certified Exome Services

Premium

Illumina has launched its TruSight One sequencing panel, which targets 4,813 genes with known associated clinical phenotypes. The panel is designed to be used in conjunction with Illumina's VariantStudio analysis and reporting software, which will also include new features that expand annotation capabilities such as support to enable family-based filtering, variant classification, and the ability to generate ready-to-use reports.


Life Technologies has added 11 new members to its Ion AmpliSeq Exome Certified Service ProgramSanford Burnham, SeqWright Genomic Services, Genewiz, Affiliated Genetics, Eureka Genomics, the University of Arizona, the University of British Columbia, Ohio State University, AltheaDx, PrimBio Research Institute, and the University of New Mexico.

In order to be certified, the institutions must be able to sequence to exomes on one run of the Ion Proton in two days, using the AmpliSeq Exome Kit, the Proton, and the Ion Reporter software.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.